India has allowed the export of the anti-malaria drug hydroxychloroquine, after the United States President Donald Trump threatened Modi government of retaliation.
According to the details, in a press briefing while giving one of the answers Trump stated ” I spoke to him (Indian Prime Minister Narendra Modi), Sunday morning & I said we appreciate it that you are allowing our supply (of anti-malaria drug Hydroxychloroquine) to come out, if he doesn’t allow it to come out, that would be okay, but of course, there may be retaliation, why wouldn’t there be?:”
It is pertinent to mention here that earlier, the government of India put a ban on exports of hydroxychloroquine as well as on the pain reliever, paracetamol, to meet its internal demand amid coronavirus pandemic spread.
A day after Trump spoke to Indian Prime Minister Modi and asked him to lift the ban or else India may face retaliation.
On the other hand Indian Ministry of External Affairs (MEA) spokesperson, Anurag Srivastava stated “It has been decided that India would license paracetamol and hydroxychloroquine in appropriate quantities to all our neighbouring countries who are dependent on our capabilities.”
Earlier in March, Trump said, a drug currently used as an antimalarial, hydroxychloroquine would be made available almost immediately to treat coronavirus.
Speaking at a news conference, Trump pointed to efforts on Gilead Sciences Inc’s experimental antiviral drug Remdesivir and the generic antimalarial drug hydroxychloroquine, and said he had called on the U.S. Food and Drug Administration to streamline its regulatory approval process.
LIVE: Press Briefing with Coronavirus Task Force https://t.co/uvFZaWbcME
— The White House (@WhiteHouse) March 19, 2020
The sources of Reuters, US President Trump said, “We have to remove every barrier.”
Trump said, “We have to remove every barrier or a lot of barriers that were unnecessary and they’ve done that to get the rapid deployment of safe, effective treatments and we think we have some good answers.”
— Dr. Stephen M. Hahn (@SteveFDA) March 19, 2020